INTRODUCTION
Prostate Specific Antigen (PSA) has become the most commonly used tumour marker for prostate cancer. PSA is a serine protease produced by the epithelial cells of normal, hyperplastic, and cancerous prostatic tissue. Because the enzyme is not specific for prostate cancer, the PSA test has a high false positive rate when used as a screening tool. Roughly one in four of men with serum PSA levels between 4.1 and 9.9 ng per ml have prostate cancer on biopsy. [1] [2] [3] [4] In men without prostate cancer, PSA levels increase with age, mainly because of increases in prostate volume due to benign prostatic hyperplasia. PSA is a continuous marker, there has been controversy about what threshold should be used to refer men for biopsy. [5] [6] [7] Cross-sectional population data suggest that the serum PSA increases 4% per mL of prostate volume, and that 30% and 5% of the variance in PSA can be accounted for by prostate volume and age, respectively.
[8] Initial studies set the upper limit of normal for PSA at 4 ng/mL, with levels greater than 10 ng/mL being suspicious for malignancy and levels of 4 to 10 ng/mL being indeterminate. Oesterling et al. developed age-specific reference ranges for white men from Olmsted County, Minnesota.
[9] Later multiple studies have suggested that age specific cutoff values for PSA screening are better than the currently used standard cutoff of 4.0ng/ml and the fact that different races have their own reference ranges.
[10-13] Nonetheless, serum PSA screening is a powerful tool for the detection of prostate cancer in both blacks and whites, and when properly applied on an individual basis, the use of agespecific reference ranges can improve the clinical value of such screening. [10] [11] [12] [13] The objective of the current study was to study the PSA values of elderly individuals attending a tertiary care centre in southern India and postulate the possible normal values of PSA in different age groups of elderly. people from all over the state visit to get comprehensive full check-up and screen for diseases. PSA is being routinely offered for all geriatric patients visiting the comprehensive geriatric check up program. 4ml blood was collected in red vaccutainor and was estimated by Chemiluminiscent Microparticle Immunoassay with micro-particle and Acridinium labeled conjugate as the reagent. All the patient clinical information is registered in a fully computerized and networked Hospital Information System (HIS).
MATERIALS AND METHODS
A total of 1038 males over the age of 60 years presenting to the Elderly Comprehensive Health clinic at the Department of Geriatrics of Amrita Institute of Medical Sciences and Research Centre, Kochi, Kerala between 1st March, 2009 to 28th February, 2011 were studied. All patients who had a Digital Rectal Examination (DRE) in the past 3 months, patients who have been catheterized in the past 3 months, those who are known cases of prostatic diseases -carcinoma prostrate, BPH, patients on 5-apha-reductase inhibitors were excluded.
Normative values were defined from individuals with a PSA value of less than 4 ng/ml and individuals with a PSA value of more than 4 ng/ml on whom biopsy was done and reported as normal. .PSA values were analyzed in terms of mean, standard deviation and 5 th and 95 Th percentiles. Amongst the non-suspicious group, 2 were lost to follow up and biopsy was done in 8 patients -of which 2 had malignancy. 18 of these patients reviewed with repeat PSA values and of which PSA rose in 12 patients -of which 3 were proven to be malignant. Amongst the 6 patients who did not reported a rise a PSA -malignancy was proven in 3 patients.
RESULTS AND DISCUSSION
Age specific reference ranges of PSA is essential in interpreting PSA of elderly and our study showed values that are similar to the expected. Interestingly, there is a fall in the mean values of PSA in higher age brackets but this is not statistically significant. The study also demonstrated that roughly 10 % of the elderly population in all age subsets had PSA values over the normal. This is comparable to other studies and conveys that routine PSA testing puts roughly 1 in 10 patients at risk for biopsy. [15] [16] [17] [18] [19] Total number of patients who had an elevated PSA more than 4 ng/ml in our study were higher when compared to other studies -8.4% with more than one-third of them being more than 10ng/ml.
[ [21] They also showed that the mean PSA level among men with prostate cancer aged 60 yr, also with normal digital rectal examination, is 2.66 ng/ml. [21] A meta-analysis of age specific analysis of PSA in elderly by Hans-Joachim et al in the European Urology Update 2007, that delved into multiple similar studies assessing age specific PSA reference values, have all demonstrated an increase in PSA values in patients aged 70-79 when compared to patients in the 60-69 age group with very few studies done on patients aged over the age of 80.
The established normal range limit of 4.0ng/mL for PSA was initially proposed in a 1986 study by Hybritech Inc., San Diego, CA, in a small population of 472 men without a history of prostate cancer. [12] Later studies of larger and more clinically relevant populations to define the optimum cutoff value with both sensitivity and specificity for cancer detection fluctuated between 2.8 and 4.0 ng/mL. [22] The sceening study of 6630 men aged 50-74, which led to the first US Food and Drug Administration (FDA) approval for early detection, assessed the efficacy of the cut off and derived at an upper limit of 3.9 in the 5054 age group. [ 23, 24] .At the time, recommendation of a biopsy for men with PSA > 4.0ng/mL was considered to be an aggressive position because PSA values greater than 10ng/mL were often viewed as the biopsy decision point.
The study had all limitations of a retrospective record study based. This was done in a private tertiary care hospital and so itself is not representative of general population. Biopsy was done only for patients who had very high PSA values or suspicious DRE findings and we could not obtain follow up information on all subjects with elevated PSA. There could have been prostrate cancers in patients with PSA values less than 4ng/ml and this could only have been evaluated if biopsy was done in all patients, irrespective of their PSA levelswhich is not the accepted medical norm. 
4.CONCLUSION
Age specific reference ranges of PSA is essential in interpreting PSA of elderly and our study in Southern India showed that the values are similar to the expected. The age specific Indians being ethnically distinct, need to have separate PSA reference ranges which need to be established with large community-based multicentre Indian studies. 
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